Samples submitted to Compounds Australia offer biologists a unique screening set.

We can perform substructure searches and similarity matching so focussed subsets can also be supplied, if desired, in addition to the complete diverse set.

Post-screening, Compounds Australia facilitates contact with sample owners for independent project follow-up and disclosure of structures. Compounds Australia does not take an ownership stake in resulting or background IP.

Available within our Open Access Academic library are ~9,000 compounds submitted by Australian universities (including ~1,000 compounds from The University of Adelaide’s Fragment collection).

Storage and access:

• Access is charged on a per plate basis
• Stored in low temperature and low humidity environments as 5mM solutions in 100% DMSO
• Available in assay-ready formats only (volumes 2.5–1000nL)
• Full libraries or single point, multi-point and cherry-picked formats
• Chemical structures are unavailable. Structure similarity searching available based on chemical fingerprints and information provided including chemical property information such as Log P, MW, HBA, HBD, PSA and chiral centres.
• Intellectual Property of the compound belongs to the sample depositor (contact with the depositor can be facilitated by Compounds Australia)

Our Open Access Drug Libraries comprise the Selleck Kinase, Epigenetics (2016), MicroSource Spectrum FDA (2015) and MedChemExpress (2021) collections. These libraries are searchable via Smart Compounds and provide researchers with biologically active and structurally diverse compounds:

• for target validation
• for assay validation
• to unlock new targets for known compounds
• to provide preliminary data for grant applications.

Storage and access:

• Access is charged on a per plate basis
• Stored in low temperature and low humidity environments as 5mM solutions in 100% DMSO
• Available in assay-ready formats only (volumes 2.5–1000nL)
• Full libraries or single point, multi-point and cherry-picked formats
• Chemical structures and source information available as provided by the chemical vendor.

Our drug libraries are further categorised into the following subcategories to assist in library selection for the researcher’s biological target:

• Epigenetics
• Anti-cancer
• Kinase inhibitors
• Tyrosine Kinase inhibitors
• Anti-infection
• CNS/Neuronal/Anti-Alzheimer
• Cell cycle
• Preclinical/Clinical
• FDA/Approved Drugs

Our Open Access Scaffolds Library includes 34,000 commercially available compounds, focused on 1,200 unique scaffolds, with an average of 28 compounds per scaffold available for follow-up screening.

We recommend screening one or two compounds per scaffold, then requesting the scaffold cluster for follow up of active compounds.

Storage and access:

• Access is charged on a per plate basis
• Available in assay-ready formats only (volumes 2.5–1000nL)
• Full libraries or single point, multi-point and cherry-picked formats
• Stored in low temperature and low humidity environments as 5mM solutions in 100% DMSO

The Fragment Library offers a curated selection of molecular fragments for fragment-based screening applications. These have been sourced from commercial vendors for accessing by Compounds Australia researchers.

The Fragment library has been curated for researchers interested in fragment-based drug discovery or probing molecular interactions at a finer scale.

Storage and access:

• Access is charged on a per plate basis (cherrypicking or plate replication)
• Stored in optimal conditions as 10mM, 50mM or 100mM solutions in 100% DMSO (Concentrations are depending on sub-library)
• Available in assay-ready formats only (volumes 2.5–1000nL)
• Full libraries or customized subsets available

Subsets include:

• Electrophilic Covalent Probes – 10mM
• Novel Fragment Diversity Set – 100mM
• ChemBridge Fragment Library (purchased in 2017) – 50mM / 100mM